Biotek-snakken — April 2023
-
2 Top Biotech Stocks to Buy Right Now https://www.proinvestor.com/investornyt/965228/2-top-biotech-stocks-to-buy-right-now
-
Danske Bank har øget sin ejerandel i biotekselskabet Gubra til 6,38 pct. af aktiekapitalen, som ejes gennem blandt andet Danica og Danske Invest.
Dermed er banken at regne som storaktionær i Gubra, der gik på børsen mandag før påske.
Det skete til en kurs på 110 kr. Og præcis i det niveau lukkede aktien onsdag, hvor den endte uændret.
.\˙ MarketWire
-
Saniona fortsætter op og der er en aktie, som er ved at rejse sig igen. Der er et kæmpe potentiale i selskabet og hvis/når de får nogle partneraftaler med blandt andet deres blockbuster Tesomet og endelig godkendelse af Tesofensine i Mexico, så er kursen nemt tilbage mellem 25-30 SEK, hvor den kom fra inden de satte deres to studier af Tesomet på standby.
-
Orphazyme på vej med forligsløsning på tvist i USA https://www.proinvestor.com/investornyt/968661/orphazyme-pa-vej-med-forligslosning-pa-tvist-i-usa
-
Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV https://www.proinvestor.com/investornyt/968741/inovio-presents-data-from-phase-1b-trial-with-ino-4201-as-ebola-booster-for-rvsv-zebov
-
Stimen af opkøb fortsætter: GSK To Buy BELLUS Health In US$2.0 Bln Deal https://www.proinvestor.com/investornyt/969145/gsk-to-buy-bellus-health-in-us20-bln-deal
-
Basilea Provides Updated Timeline For NDA Submission For Antibiotic Ceftobiprole To FDA https://www.proinvestor.com/investornyt/969136/basilea-provides-updated-timeline-for-nda-submission-for-antibiotic-ceftobiprole-to-fda
-
FDA Approves Omisirge Cell Therapy For Blood Cancers https://www.proinvestor.com/investornyt/969139/fda-approves-omisirge-cell-therapy-for-blood-cancers
-
Pyramid Bio bets on GeneQuantum's ADC candidate for over $1 billion https://firstwordpharma.com/story/5727433
-
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting https://firstwordpharma.com/story/5728539
-
Oxford biotech firm secures £13.2m to develop world’s first treatment for rare, incurable and deadly disease https://firstwordpharma.com/story/5727697
-
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics https://firstwordpharma.com/story/5727677
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind